DANIEL BRADBURY - 01 Feb 2023 Form 4 Insider Report for CASTLE BIOSCIENCES INC (CSTL)

Role
Director
Signature
/s/ Greg Acosta, Attorney-in-fact
Issuer symbol
CSTL
Transactions as of
01 Feb 2023
Net transactions value
-$686,928
Form type
4
Filing time
03 Feb 2023, 15:18:04 UTC
Previous filing
04 Jan 2023
Next filing
06 Mar 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CSTL Common Stock Sale $200,851 -7,445 -3.7% $26.98 192,094 01 Feb 2023 By LLC F1, F2, F3
transaction CSTL Common Stock Sale $66,932 -2,481 -2.5% $26.98 95,299 01 Feb 2023 By Daniel Bradbury Irrecovable Descendant's Trust F1, F2, F4
transaction CSTL Common Stock Sale $66,959 -2,482 -2.5% $26.98 95,323 01 Feb 2023 By Annette Bradbury Irrecovable Descendant's Trust F1, F2, F5
transaction CSTL Common Stock Sale $122,451 -4,451 -2.3% $27.51 187,643 01 Feb 2023 By LLC F1, F3, F6
transaction CSTL Common Stock Sale $40,826 -1,484 -1.6% $27.51 93,815 01 Feb 2023 By Daniel Bradbury Irrecovable Descendant's Trust F1, F4, F6
transaction CSTL Common Stock Sale $40,799 -1,483 -1.6% $27.51 93,840 01 Feb 2023 By Annette Bradbury Irrecovable Descendant's Trust F1, F5, F6
transaction CSTL Common Stock Sale $76,623 -2,684 -1.4% $28.55 184,959 02 Feb 2023 By LLC F1, F3, F7
transaction CSTL Common Stock Sale $25,550 -895 -0.95% $28.55 92,920 02 Feb 2023 By Daniel Bradbury Irrecovable Descendant's Trust F1, F4, F7
transaction CSTL Common Stock Sale $25,550 -895 -0.95% $28.55 92,945 02 Feb 2023 By Annette Bradbury Irrecovable Descendant's Trust F1, F5, F7
transaction CSTL Common Stock Sale $12,231 -420 -0.23% $29.12 184,539 02 Feb 2023 By LLC F1, F3, F8
transaction CSTL Common Stock Sale $4,077 -140 -0.15% $29.12 92,780 02 Feb 2023 By Daniel Bradbury Irrecovable Descendant's Trust F1, F4, F8
transaction CSTL Common Stock Sale $4,077 -140 -0.15% $29.12 92,805 02 Feb 2023 By Annette Bradbury Irrecovable Descendant's Trust F1, F5, F8
holding CSTL Common Stock 830 01 Feb 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC on November 23, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $26.320 to $27.315, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.
F4 Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
F5 Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
F6 This transaction was executed in multiple trades at prices ranging from $27.320 to $27.905, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $28.100 to $29.035, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $29.105 to $29.145, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.